Oruka Therapeutics (ORKA) EBITDA (2010 - 2024)

Oruka Therapeutics' EBITDA history runs 15 years deep, the most recent figure standing at -$3.1 million for Q2 2024.

• In Q2 2024, EBITDA fell 58.24% year-over-year to -$3.1 million; the TTM figure through Jun 2024 stood at -$9.1 million (down 16.04% YoY), while the FY2023 annual figure was -$7.3 million, up 31.14% from the prior year.
• EBITDA for Q2 2024 stood at -$3.1 million, down from -$2.5 million in the prior quarter.
• The five-year high for EBITDA was -$1.3 million in Q2 2020, with the low at -$5.7 million in Q4 2021.
• The 5-year median for EBITDA is -$2.5 million (2022), against an average of -$2.9 million.
• The sharpest annual moves came in 2020 and 2022: EBITDA sank 301.1% in 2020, then surged 72.75% in 2022.
• Oruka Therapeutics' EBITDA stood at -$5.1 million in 2020, then decreased by 10.81% to -$5.7 million in 2021, then soared by 72.75% to -$1.5 million in 2022, then slipped by 2.71% to -$1.6 million in 2023, then sank by 96.35% to -$3.1 million in 2024.
• Business Quant data shows ORKA's EBITDA at -$3.1 million in Q2 2024, -$2.5 million in Q1 2024, and -$1.6 million in Q4 2023.